Your browser doesn't support javascript.
loading
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Zhao, Jun; Yu, Xinmin; Huang, Dingzhi; Ma, Zhiyong; Gao, Bo; Cui, Jiuwei; Chu, Qian; Zhou, Qing; Sun, Meili; Day, Daphne; Wu, Jingxun; Pan, Hongming; Wang, Lifeng; Voskoboynik, Mark; Wang, Zhehai; Liu, Yunpeng; Li, Hui; Zhang, Juan; Peng, Yanyan; Wu, Yi-Long.
Afiliación
  • Zhao J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
  • Yu X; Department of Medical Oncology, Cancer Hospital of University of Chinese Academy of Sciences & Zhejiang Cancer Hospital, Hangzhou, China.
  • Huang D; Department of Thoracic Medical Oncology, Tianjin Cancer Hospital, Tianjin, China.
  • Ma Z; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital, Zhengzhou, China.
  • Gao B; Blacktown Hospital and University of Sydney, Sydney, New South Wales, Australia.
  • Cui J; Cancer Center, The First Hospital of Jilin University, Changchun, China.
  • Chu Q; Department of Oncology, Tongji Hospital, Wuhan, China.
  • Zhou Q; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Sun M; Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, China.
  • Day D; Medical Oncology, Monash Health and Monash University, Melbourne, Victoria, Australia.
  • Wu J; Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
  • Pan H; Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.
  • Wang L; Nanjing Drum Tower Hospital, Nanjing, China.
  • Voskoboynik M; Medical Oncology, Nucleus Network, Melbourne, VIC, Australia and Central Clinical School, Monash University, Melbourne, Victoria, Australia.
  • Wang Z; Department of Internal Medicine - Oncology, Shandong Cancer Hospital & Institute, Jinan, China.
  • Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
  • Li H; BeiGene (Shanghai) Co., Ltd, Shanghai, China.
  • Zhang J; BeiGene (Beijing) Co., Ltd, Beijing, China.
  • Peng Y; BeiGene (Shanghai) Co., Ltd, Shanghai, China.
  • Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China syylwu@live.cn.
J Immunother Cancer ; 11(2)2023 02.
Article en En | MEDLINE | ID: mdl-36808075
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Crocus / Neoplasias Pulmonares Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Crocus / Neoplasias Pulmonares Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article País de afiliación: China